Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1061-1080 of 1,738 trials

Cerebrolysin for CADASIL Patients

We are studying whether Cerebrolysin is safe and effective for individuals with genetically confirmed CADASIL. This trial compares it to a placebo to understand its overall benefits.

CADASIL>2 yearsEfficacy phase (II)>20 visitsStandard MedicinesNeurology

Efgartigimod for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will evaluate the safety, dosing, and effects of this treatment on their daily lives.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Achondroplasia: Long-Term Study of Infigratinib

We are studying the long-term safety and effects of Infigratinib in children with Achondroplasia. The goal is to see how it impacts their growth and overall health.

Achondroplasia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Advanced Solid Tumors: GSK5733584 Injection

We are evaluating a new injection for people with advanced solid tumors to see if it is safe and how well it works. This study aims to understand the drug's effects on patients.

Ovarian Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Chronic Kidney Disease: Sevuparin Treatment Study

We are investigating how sevuparin may improve kidney function and anemia in people with chronic kidney disease. The study will assess safety and how the drug works in the body.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyNephrology

Cluster Headache Study: Understanding Brain Activity

We are exploring how brain activity and receptor availability differ in people with cluster headaches during active and inactive periods. This research may help us learn more about the condition and its effects on the brain.

Nervous System Diseases>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

Glucose Distribution in Severely Burned Adults

We are studying how glucose is distributed in the bodies of severely burned adults during their first few days of treatment. This research may help us understand its relationship with other health factors and improve patient care.

Severe Burns>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyInternal MedicineOrthopedics and Traumatology

Pancreatic Cancer: TCR-Modified T-Cell Therapy

We are studying a new therapy using modified T-cells for adults with advanced pancreatic cancer that has specific genetic mutations. The trial aims to assess safety and how well this treatment may work.

Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Rectal Cancer: Valproic Acid with Radiotherapy and Capecitabine

We are studying whether adding valproic acid to standard radiotherapy and capecitabine improves tumor response in patients with low to moderate risk rectal cancer before surgery. This trial also examines the impact on survival and quality of life.

Rectal CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Locally Advanced Rectal Cancer: CApecitabine and Temozolomide Study

We are studying a new treatment combining capecitabine and temozolomide for patients with specific types of locally advanced rectal cancer. The goal is to see if this combination improves tumor response and surgical outcomes.

Locally Advanced Rectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Metastatic Breast Cancer: Next Generation Sequencing Oncochip

We are studying a new sequencing tool to help decide the best treatment for metastatic breast cancer patients. The goal is to see if it improves survival and response compared to standard chemotherapy.

Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HIV Treatment: IMC-M113V Study

We are evaluating a new treatment, IMC-M113V, for people with chronic HIV infection who are already on medication. The study will help us understand its safety and how it affects the immune system.

Chronic HIV Infection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

New Treatment for Limbal Stem Cell Deficiency: Oral Mucosa Cells

We are testing a new method using cultured cells from the mouth to help people with limbal stem cell deficiency. This study aims to see if this treatment can improve eye health and vision.

Limbal Stem Cell Deficiency>2 yearsSafety phase (I)Efficacy phase (II)Ophthalmology

Hepatocellular Carcinoma: Durvalumab and Tremelimumab with Y-90 SIRT

We are studying a combination of immunotherapy and radiation therapy for patients with intermediate stage liver cancer who cannot have surgery. The goal is to see if this treatment can help shrink tumors and improve survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHepatologyOncology

TBR1-Related Neurocognitive Disorder: Lithium Carbonate Study

We are studying whether lithium carbonate can improve behavior and communication in patients with TBR1-related neurocognitive disorder. This trial will also assess the treatment's safety and overall impact on quality of life.

TBR1 Variant>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPsychiatry

GIST Treatment: Lenvatinib vs. Placebo

We are evaluating whether lenvatinib can help patients with advanced GIST who did not respond to imatinib and sunitinib. This study compares its effects to a placebo to assess its potential benefits.

Metastatic Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesOncology

Papillary Renal Cell Carcinoma: Axitinib with or without Pembrolizumab

We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.

Metastatic Renal Cell CarcinomaLocally Advanced or Metastatic Papillary Cell Carcinoma3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Pulmonary Hypertension: Mosliciguat Study

We are testing the medication Mosliciguat for individuals with pulmonary hypertension related to interstitial lung disease. The study aims to see if it helps improve heart function and walking ability.

Pulmonary Hypertension6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Venous Thromboembolism in Cancer: Abelacimab vs. Dalteparin

We are studying whether a new medication, abelacimab, can effectively prevent blood clots in patients with gastrointestinal or genitourinary cancer. This trial compares it to the standard treatment, dalteparin.

Venous Thromboembolism (VTE)6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Vibegron for Children with Neurogenic Detrusor Overactivity

We are studying the safety and effectiveness of vibegron in children aged 2 to under 18 with neurogenic detrusor overactivity who use clean intermittent catheterization. This trial aims to understand how well the medication works and how it is processed in young patients.

Neurogenic Bladder1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsUrology